jueves, 22 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· March 26, 2026

BYDFi rozszerza swoją obecność w Europie, sponsorując targi Next Block Expo 2026 w Warszawie

View original at globenewswire.com
BYDFi rozszerza swoją obecność w Europie, sponsorując targi Next Block Expo 2026 w Warszawie WARSZAWA, Polska, March 26, 2026 (GLOBE NEWSWIRE) -- Globalna platforma handlu kryptowalutami BYDFi wspiera jako sponsor targi Next Block Expo 2026, które odbywają się w dniach 24–25 marca w Warszawie…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • As the market matures, long-term trust is gained through clear communication, consistent standards, and responsible approach to operating in it

    60% confidence

  • BYDFi is committed to providing users with the highest quality service and experience during cryptocurrency trading

    60% confidence

  • Next Block Expo focuses on topics that currently matter most - infrastructure, legal regulations, product design, and how people actually participate in the market. For BYDFi this is a valuable opportunity to listen to user feedback, connect with them, and continuously improve the trading platform that was designed from the beginning with reliability in mind and has gained user trust

    60% confidence

Citado en estos reportajes de Via News

Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Q4 2026 Biopharma Catalyst Crunch: Late-Stage Readouts and Regulatory Milestones Converge on the Ivonescimab PDUFA Date
October 2026 is dense with clinical and regulatory news. Phase 3 trials hit primary endpoints (ALOFT-IPF, RESTORE-3), long-term data came out (MIUDELLA at 6 years, QUILT-3.032), and the FDA accepted Roche's vamikibart BLA. Scholar Rock resubmitted its apitegromab MAA to the EMA. The next catalysts are ESMO 2026 (Oct 23) and the Nov 14 FDA PDUFA date for ivonescimab, followed by Maritime-1 primary completion in January 2027. The speculative QAIAx items (QIII pilot, microcities patent) are a weak, tangential thread with little financial substance.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,426 documentos fuente archivados
Consulta estos datos → isubstrate.com